XSpray Pharma AB (publ) banner

XSpray Pharma AB (publ)
F:6XP

Watchlist Manager
XSpray Pharma AB (publ) Logo
XSpray Pharma AB (publ)
F:6XP
Watchlist
Price: 2.085 EUR -2.11% Market Closed
Market Cap: €60.4m

Wall St Price Targets

6XP Price Targets Summary
XSpray Pharma AB (publ)

Wall Street analysts forecast 6XP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 6XP is 4.854 EUR with a low forecast of 4.807 EUR and a high forecast of 4.997 EUR.

Lowest Forecast
Price Target
4.807 EUR
131% Upside
Average Forecast
Price Target
4.854 EUR
133% Upside
Highest Forecast
Price Target
4.997 EUR
140% Upside
XSpray Pharma AB (publ) Competitors:
Price Targets
ELAN
Elanco Animal Health Inc
26% Upside
WLFC
Willis Lease Finance Corp
-19% Downside
VNOM
Viper Energy Partners LP
21% Upside
1981
Cathay Media and Education Group Inc
35% Upside
AMSF
Amerisafe Inc
26% Upside
WOOF
Petco Health and Wellness Company Inc
31% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 6XP's stock price target?
Price Target
4.854 EUR

According to Wall Street analysts, the average 1-year price target for 6XP is 4.854 EUR with a low forecast of 4.807 EUR and a high forecast of 4.997 EUR.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett